• linkedin
  • Increase Font
  • Sharebar

    Anticholinergic cycling not effective in OAB with UI

    Daily incontinence episodes similar regardless of number of agents tried

    Royal Oak, MIThe adage, “If at first you don’t succeed, try, try again,” does not appear to hold true when it comes to anticholinergic drug use in overactive bladder patients with urinary incontinence, recent study results indicate.

    ALSO READ: FDA approves prosthesis for women with underactive bladder

    With several anticholinergic agents available to treat OAB patients with urinary incontinence, opinions vary as to how many should be tried, first author Michael Chancellor, MD, explained to Urology Times. 

    To evaluate anticholinergic cycling, Dr. Chancellor and colleagues conducted a retrospective claims analysis linked to a patient survey administered to OAB patients from a California-based accountable care organization (ACO). Patients had at least one diagnosis of OAB and at least one urinary incontinence episode per day and initiated anticholinergic therapy between January 2008 and May 2012. Anticholinergic cycling was defined as moving from one unique anticholinergic to another.

    The authors found that patient discontinuation of anticholinergic agents was high, with 467 of the 655 patients stopping use of the medication. The majority of patients tried one anticholinergic (426), 176 tried two agents, 39 tried three, and 14 tried four or more, reported Dr. Chancellor, professor of urology and director of neurourology at Beaumont Health System, Oakland University William Beaumont School of Medicine, Royal Oak, MI. One patient tried six agents, and failed all six.

    The authors found that the number of urinary incontinence episodes per day was similar regardless of the number of anticholinergics attempted and regardless of whether patients continued or discontinued therapy. In addition, most patients were still bothered by bladder symptoms regardless of whether they continued or discontinued therapy.

    Next: Findings a 'game changer'

    You might also like:

    ‘Continued success’ seen with botulinum injections

    Falls in the elderly: How urologists can save a life

    Ureteral injury to blame for bladder cancer, death?

    Benjamin P. Saylor
    Saylor is content managing editor for Urology Times.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available